American Society of Hirudotherapy

Pigrin

Selective PAR1 antagonist from non-hematophagous Whitmania pigra — Ren 2019 demonstrates antithrombotic activity in rat without prolonging bleeding time.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Last Updated: May 27, 2026 · ASH Editorial · based on the books
  • Hementerin80 kDa
  • Hementin80 kDa
  • Hementin-Like Protein (HLP-1)80 kDa
  • Leech Collagenase70 kDa
  • Haemadipsa yanyuanensis Progranulin (Hy-PGRN)70 kDa
  • Leech Apyrase67 kDa
  • Calin65 kDa
  • Hyaluronidase60 kDa
  • Antithrombin III binding protein58 kDa
  • Collagenolytic Fibrinolysin55 kDa
  • Leech Thrombospondin-Like Protein50 kDa
  • Pigrin8.5 kDa
Molecular weight (kilodaltons) of Pigrin (highlighted) alongside other characterized leech salivary compounds. Smaller proteins/peptides generally diffuse and act faster.

Mechanistic Evidence Box

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.
Page type
Compound profile
Evidence type
Preclinical / biochemical characterization
Evidence level
Preclinical (animal)
Drug vs leech
Recombinant (genetically expressed)
Safety domains
Bleeding

Clinical translation limit

Pigrin's preclinical PAR1 antagonism + antithrombotic activity does NOT establish clinical efficacy. No FDA-approved derivative exists; W. pigra is a non-hematophagous TCM leech not on the FDA K040187 cleared species list. The 'no bleeding tendency' finding is from rodent models and cannot be extrapolated to human bleeding risk.

Molecular Profile

Category
Antiplatelet
Evidence tier
Preclinical
Molecular weight
8,500 Da
Source species
Whitmania pigra
Discovered
2019 · Ren SH et al.

Biological Targets

  • → protease-activated receptor 1 (PAR1)
  • → collagen-platelet interaction

Key Citations

  1. Ren SH et al. (2019), Chin J Nat Med · PMID 31472896

External Resources

    Related Antiplatelet Compounds

    This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.